Fujifilm Invests $1.6 Billion into Expanding its Cell Culture Manufacturing Services
SHARE NOW
Fujifilm Corporation has announced a $1.6 billion investment into Fujifilm Diosynth Biotechnologies’ cell culture manufacturing services, to expand and enhance the offerings of this world-leading CDMO at its sites in Hillerod, Denmark, and Texas, U.S.
In its Denmark facility, Fujifilm Diosynth Biotechnologies will use part of the investment to expand its manufacturing capacity to support large-scale cGMP fed-batch production, by adding two downstream processing streams and eight 20,000L bioreactors – creating a total of twenty 20,000L bioreactors for drug substance production.
The addition of this extra production capacity will see Fujifilm’s Hillerod Facility become the largest end-to-end CDMO in Europe and is expected to create approximately 450 jobs.
The Hillerod expansion promises to support Fujifilm’s new Green Value Climate Strategy by including enhanced sustainability measures such as fitting electric boilers in place of conventional natural gas-powered boilers, as the Company strives to be operating on carbon-free energy with net-zero CO2 emissions by the end of 2040. Fujifilm Diosynth Biotechnologies is also investing in programs to reduce water consumption.
“Fujifilm Diosynth Biotechnologies offers a comprehensive portfolio of cell culture development and manufacturing services to support its partners in navigating the clinical journey through to commercial launch and reliable supply of antibodies to help our customers deliver medicines to patients. [The expansion] will globally accelerate the deployment of its fully integrated continuous cGMP production capability to enable efficient manufacture of antibodies at a high-volume,” said Martin Meeson, CEO, Fujifilm Diosynth Biotechnologies.
At its Texan site, Fujifilm Diosynth Biotechnologies will use the investment to expand its single-use cell culture manufacturing capacity.
By implementing the fully automated and customizable technology platform SymphonXTM it will create an integrated end-to-end cGMP MaruXTM purification and continuous bio-manufacturing process, improving the efficiency and consistency of high-quality antibody production.
“With this major investment in the large-scale production facility and the deployment of the next generation production technology, we will be the best partner for customers as the premier bio CDMO. Fujifilm will, through creation of new value from innovation, contribute to the stable supply of high-quality biopharmaceuticals, and to promoting a healthy society and further growth of healthcare industry,” commented Teiichi Goto, President and CEO, Fujifilm Corporation.
Source: Fujifilm Diosynth Biotechnologies Press Release
Find out more about and register your place at Phacilitate’s Advanced Therapies Europe 2022 here >>
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
